U-RLFTD

Q:RLFTD - RELIEF THERAPEUTICS HOLDING AG SPON ADR EACH REP 1 ORD SHS - Website unknown - click to update

18:48:10 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
RLFTD - Q	not subscribed					4.08							18.00 7.5002	May 23	Sep 15	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
OTC Markets Indicators -- Primary Market: OTC Markets -- Tier: OTCQB -- Status: Active

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Portfolio

Recent Trades - All 0 today

More trades...

Time ET	Ex	Price	Change	Volume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2023-09-15 04:30	U:RLFT	News Release200	Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
2023-08-30 17:40	U:RLFT	News Release200	Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics
2023-06-23 01:31	U:RLFT	News Release200	RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
2023-06-23 01:31	U:RLFT	News Release200	Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE(R) in the Middle East
2023-06-20 05:21	U:RLFT	News Release200	RELIEF THERAPEUTICS Holding SA Announces ‚ Results of Annual General Meeting of Shareholders
2023-06-16 01:30	U:RLFT	News Release200	RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
2023-05-26 01:21	U:RLFT	News Release200	RELIEF THERAPEUTICS Holding SA Announces ‚ Notice of Annual General Meeting of Shareholders

Date ET

Symbol

Type

Headline

2023-09-15 04:30

U:RLFT

News Release

Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update

2023-08-30 17:40

U:RLFT

News Release

Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics